Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) shares crossed below its 50 day moving average during trading on Monday following insider selling activity. The stock has a 50 day moving average of $302.03 and traded as low as $300.55. Ligand Pharmaceuticals shares last traded at $301.71, with a volume of 187,061 shares changing hands.
Specifically, Director Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $318.17, for a total value of $636,340.00. Following the transaction, the director owned 1,782 shares in the company, valued at $566,978.94. This trade represents a 52.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Kozarich sold 500 shares of the business’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $325.00, for a total transaction of $162,500.00. Following the completion of the sale, the director directly owned 42,122 shares of the company’s stock, valued at $13,689,650. This represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In other Ligand Pharmaceuticals news, Director Jason Aryeh sold 3,000 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total transaction of $960,150.00. Following the completion of the sale, the director directly owned 105,476 shares in the company, valued at $33,757,593.80. This represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Analysts Set New Price Targets
Several research firms have recently commented on LGND. Royal Bank Of Canada lifted their price objective on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a report on Friday, October 30th. Weiss Ratings lowered Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research note on Monday, November 2nd. Leerink Partners started coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They set an “outperform” rating and a $330.00 target price for the company. Barclays raised their price target on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 11th. Finally, Citigroup lifted their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Ligand Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $355.38.
Check Out Our Latest Stock Analysis on LGND
Ligand Pharmaceuticals Trading Down 2.3%
The stock has a market capitalization of $6.03 billion, a P/E ratio of 134.69, a P/E/G ratio of 5.52 and a beta of 1.16. The firm’s 50 day moving average price is $302.03 and its 200 day moving average price is $258.58. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The company had revenue of $78.75 million during the quarter, compared to analyst estimates of $77.00 million. During the same period in the prior year, the business posted $3.09 earnings per share. Ligand Pharmaceuticals’s revenue for the quarter was down 31.8% on a year-over-year basis. As a group, equities research analysts expect that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Ligand Pharmaceuticals
A number of large investors have recently made changes to their positions in LGND. Cetera Investment Advisers increased its stake in shares of Ligand Pharmaceuticals by 2.5% during the third quarter. Cetera Investment Advisers now owns 3,833 shares of the biotechnology company’s stock valued at $1,197,000 after buying an additional 95 shares during the period. Entropy Technologies LP bought a new position in shares of Ligand Pharmaceuticals during the third quarter valued at approximately $3,102,000. Pathstone Holdings LLC raised its holdings in shares of Ligand Pharmaceuticals by 57.2% during the third quarter. Pathstone Holdings LLC now owns 1,857 shares of the biotechnology company’s stock valued at $580,000 after acquiring an additional 676 shares in the last quarter. Marshall Wace LLP purchased a new stake in Ligand Pharmaceuticals in the third quarter worth $9,904,000. Finally, AlphaGrep UK Ltd purchased a new stake in Ligand Pharmaceuticals in the third quarter worth $394,000. 91.28% of the stock is currently owned by institutional investors.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
See Also
- Five stocks we like better than Ligand Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
